Brief: Angion Biomedica- Expects To Report Cash And Cash Equivalents As Of June 30, 2022, Totaling Over $60 Million When It Reports Its Q2 Earnings In August 2022
29/06/2022 22:54
June 29 (Reuters) - Angion Biomedica Corp ANGN.O :
* ANGION BIOMEDICA-EXPECTS TO REPORT CASH AND CASH
EQUIVALENTS AS
OF JUNE 30, 2022, TOTALING OVER $60 MILLION WHEN IT REPORTS ITS
Q2 EARNINGS IN AUGUST 2022
Further company coverage: ANGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)